The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Updated ELN recommendations for MRD monitoring in AML: key insights and takeaways
Maria Teresa Voso, MD, University Tor Vergata, Rome, Italy, shares insights into the updated measurable residual disease (MRD) recommendations published by the ELN in December 2025 for monitoring acute myeloid leukemia (AML), highlighting the inclusion of molecular markers such as FLT3-ITD. Dr Voso outlines the revised follow-up recommendations for acute promyelocytic leukemia (APL), and notes that NPM1 remains a key MRD marker, while flow cytometry is used for patients without trackable mutations. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So in December 2025 ELN published the updated MRD recommendations including some specific AML subtypes and also including new methodologies. So we now have FLT ITD MRD, studied by NGS, which can be used for MRD studies, in addition, for instance, to NPM1, since we have frequent positivity for both markers and for APL, the newer recommendation also, as in the past, confirmed that after 24 months we can stop follow-up in high-risk APL and while for lower risk for standard risk APL molecular follow-up is no longer recommended...
So in December 2025 ELN published the updated MRD recommendations including some specific AML subtypes and also including new methodologies. So we now have FLT ITD MRD, studied by NGS, which can be used for MRD studies, in addition, for instance, to NPM1, since we have frequent positivity for both markers and for APL, the newer recommendation also, as in the past, confirmed that after 24 months we can stop follow-up in high-risk APL and while for lower risk for standard risk APL molecular follow-up is no longer recommended. For NPM1 mutated AML and also for AML with CBF there is no major change in MRD studies, with the exception of low-level MRD, which is now considered as a new definition, for instance, for NPM1-mutated AML. And flow cytometry is confirmed as the preferred method for those patients who do not have a molecular marker.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
